Targeted treatments for symptom domains in child and adolescent autism

Eric Hollander, Ann T. Phillips, Chin Chin Yeh

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Context: The number of people with autism spectrum disorders has dramatically increased over the past decade, and problem behaviours in autism are an increasing challenge to families, schools, physicians, and other health-care professionals. Pharmacological treatments can effectively target problem behaviours associated with autism. Starting point: Recently, L Namerow and colleagues (J Dev Behav Pediatr 2003; 24: 104-08) presented preliminary data in children and adolescents with autism treated with citalopram, which suggested that selective serotonin-reuptake inhibitors are useful in the reduction of symptom domains such as repetitive behaviours and mood disorders. J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients. These and other studies show how developments in study design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Where next? In therapeutic intervention the risk of treatment toxicity must be balanced against the benefits of improved symptom severity. The newer methods enable informed decisions about which patients will benefit from which treatments. Other symptom domains within autism and effects on development need to be evaluated in adequately designed clinical trials. Future strategies include extending treatment to children as young as the preschool years.

Original languageEnglish (US)
Pages (from-to)732-734
Number of pages3
JournalLancet
Volume362
Issue number9385
DOIs
StatePublished - Aug 30 2003
Externally publishedYes

Fingerprint

Autistic Disorder
Therapeutics
Citalopram
Risperidone
Family Physicians
Serotonin Uptake Inhibitors
Aggression
Mood Disorders
Intelligence
Mental Disorders
Patient Selection
Antipsychotic Agents
Outcome Assessment (Health Care)
Clinical Trials
Pharmacology
Delivery of Health Care
Wounds and Injuries
Problem Behavior

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeted treatments for symptom domains in child and adolescent autism. / Hollander, Eric; Phillips, Ann T.; Yeh, Chin Chin.

In: Lancet, Vol. 362, No. 9385, 30.08.2003, p. 732-734.

Research output: Contribution to journalArticle

Hollander, Eric ; Phillips, Ann T. ; Yeh, Chin Chin. / Targeted treatments for symptom domains in child and adolescent autism. In: Lancet. 2003 ; Vol. 362, No. 9385. pp. 732-734.
@article{a21268e27425406a8b31acbec51379e0,
title = "Targeted treatments for symptom domains in child and adolescent autism",
abstract = "Context: The number of people with autism spectrum disorders has dramatically increased over the past decade, and problem behaviours in autism are an increasing challenge to families, schools, physicians, and other health-care professionals. Pharmacological treatments can effectively target problem behaviours associated with autism. Starting point: Recently, L Namerow and colleagues (J Dev Behav Pediatr 2003; 24: 104-08) presented preliminary data in children and adolescents with autism treated with citalopram, which suggested that selective serotonin-reuptake inhibitors are useful in the reduction of symptom domains such as repetitive behaviours and mood disorders. J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients. These and other studies show how developments in study design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Where next? In therapeutic intervention the risk of treatment toxicity must be balanced against the benefits of improved symptom severity. The newer methods enable informed decisions about which patients will benefit from which treatments. Other symptom domains within autism and effects on development need to be evaluated in adequately designed clinical trials. Future strategies include extending treatment to children as young as the preschool years.",
author = "Eric Hollander and Phillips, {Ann T.} and Yeh, {Chin Chin}",
year = "2003",
month = "8",
day = "30",
doi = "10.1016/S0140-6736(03)14236-5",
language = "English (US)",
volume = "362",
pages = "732--734",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9385",

}

TY - JOUR

T1 - Targeted treatments for symptom domains in child and adolescent autism

AU - Hollander, Eric

AU - Phillips, Ann T.

AU - Yeh, Chin Chin

PY - 2003/8/30

Y1 - 2003/8/30

N2 - Context: The number of people with autism spectrum disorders has dramatically increased over the past decade, and problem behaviours in autism are an increasing challenge to families, schools, physicians, and other health-care professionals. Pharmacological treatments can effectively target problem behaviours associated with autism. Starting point: Recently, L Namerow and colleagues (J Dev Behav Pediatr 2003; 24: 104-08) presented preliminary data in children and adolescents with autism treated with citalopram, which suggested that selective serotonin-reuptake inhibitors are useful in the reduction of symptom domains such as repetitive behaviours and mood disorders. J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients. These and other studies show how developments in study design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Where next? In therapeutic intervention the risk of treatment toxicity must be balanced against the benefits of improved symptom severity. The newer methods enable informed decisions about which patients will benefit from which treatments. Other symptom domains within autism and effects on development need to be evaluated in adequately designed clinical trials. Future strategies include extending treatment to children as young as the preschool years.

AB - Context: The number of people with autism spectrum disorders has dramatically increased over the past decade, and problem behaviours in autism are an increasing challenge to families, schools, physicians, and other health-care professionals. Pharmacological treatments can effectively target problem behaviours associated with autism. Starting point: Recently, L Namerow and colleagues (J Dev Behav Pediatr 2003; 24: 104-08) presented preliminary data in children and adolescents with autism treated with citalopram, which suggested that selective serotonin-reuptake inhibitors are useful in the reduction of symptom domains such as repetitive behaviours and mood disorders. J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients. These and other studies show how developments in study design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Where next? In therapeutic intervention the risk of treatment toxicity must be balanced against the benefits of improved symptom severity. The newer methods enable informed decisions about which patients will benefit from which treatments. Other symptom domains within autism and effects on development need to be evaluated in adequately designed clinical trials. Future strategies include extending treatment to children as young as the preschool years.

UR - http://www.scopus.com/inward/record.url?scp=0042329245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042329245&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14236-5

DO - 10.1016/S0140-6736(03)14236-5

M3 - Article

VL - 362

SP - 732

EP - 734

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9385

ER -